The American Journal of Pharmacy Benefits
The authors examined trends in the utilization of prescription opioid medication following introduction of abuse deterrent technology for Oxycontin.
This paper explores the economic incentives that oncologists face when deciding between oral and intravenous oncolytics and their impact on prescribing behavior.
This study characterizes the role of specialty drug utilization in aggregate private sector healthcare spending in the United States from 2000 to 2009.
Among rheumatoid arthritis patients newly treated with adalimumab, etanercept, or infliximab, lower dose escalation rates and costs were seen with etanercept.
This article reviews current drug therapies for heart failure and therapy integration into a patient care framework improving patient adherence and quality of life and decreasing risk of readmission to acute care facilities.
To achieve the triple aim, the healthcare benefit and the pharmacy benefit must evolve.